McCarthy P, Hurd D, Rowlings P, Crump M, Gale R, Lazarus H, Vaughan W, Weinberger B, Wiemann M, Freytes C, Cirenza E, Antman K
Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.
Bone Marrow Transplant. 1999 Aug;24(4):365-8. doi: 10.1038/sj.bmt.1701926.
The purpose of this study was to determine the outcome of high-dose therapy with autologous hematopoietic stem cell support (autotransplants) in men with breast cancer. We studied 13 men receiving autotransplants for breast cancer and reported to the Autologous Blood and Marrow Transplant Registry (ABMTR) by 10 centers. Six men had stage 2 breast cancer, four had stage 3, and three had metastatic breast cancer. Of twelve tumors tested, all were estrogen receptor positive. Median age at transplant was 50 years. The most common conditioning regimen was cyclophosphamide, thiotepa and carboplatin (n = 5); the remaining eight men received other alkylator-based regimens. Three men received bone marrow, eight received blood stem cells, and two received both for hematopoietic support. All patients had hematopoietic recovery. There were no unexpected regimen-related toxicities. Of 10 men receiving autotransplants as adjuvant therapy, three relapsed 3, 5 and 50 months post-transplant and died 16, 19 and 67 months post-transplant. Seven of 10 are disease-free with median follow-up of 23 months (range 6-50 months). Of three men treated for metastatic breast cancer, one had progressive disease and two recurrent disease at 6, 7 and 16 months post-transplant. In conclusion, results of autotransplants for male breast cancer appear similar to those reported for women receiving autotransplants for breast cancer.
本研究的目的是确定采用自体造血干细胞支持的高剂量疗法（自体移植）治疗男性乳腺癌的效果。我们研究了13名接受乳腺癌自体移植的男性，这些病例由10个中心上报至自体血液和骨髓移植登记处（ABMTR）。其中6名男性患有2期乳腺癌，4名患有3期乳腺癌，3名患有转移性乳腺癌。在检测的12个肿瘤中，所有肿瘤雌激素受体均为阳性。移植时的中位年龄为50岁。最常用的预处理方案是环磷酰胺、噻替派和卡铂（n = 5）；其余8名男性接受了其他基于烷化剂的方案。3名男性接受了骨髓移植，8名接受了造血干细胞移植，2名同时接受了两者用于造血支持。所有患者造血功能均得以恢复。未出现意外的与方案相关的毒性反应。在10名接受自体移植作为辅助治疗的男性中，3人在移植后3、5和50个月复发，并于移植后16、19和67个月死亡。10名患者中有7名无疾病复发，中位随访时间为23个月（范围6 - 50个月）。在3名接受转移性乳腺癌治疗的男性中，1人在移植后6、7和16个月出现疾病进展，2人出现疾病复发。总之，男性乳腺癌自体移植的结果似乎与女性乳腺癌自体移植的报道结果相似。
